| Followers | 8 |
| Posts | 750 |
| Boards Moderated | 0 |
| Alias Born | 10/19/2008 |
Saturday, March 01, 2014 12:07:58 PM
You appear to be just a person trying to be a good investor by not totally discounting what can come of things, ligitimate or not.
I appreciate your candor and approach. It is certainly posible that NNVC has not been perfect at executing its business and developmental iniciatives. However is sincerely doubt anything they may have done was nefarious in any way. Do they want to protect their interests, I would think so. Are they a group of honest doctors trying to save lives, I also think that is true. Are they out there to steal from investors, I think not. Is it possible they may have headwinds due to possible misteps and/or mistakes...well of course.
Overall though, you simply appear to be a very cautious investor. The fact that such a cautious investor is considering the merits of NNVC, I see as a plus.
Welcome aboard. All thoughtfull comments that are made without malice or without manipulative motives are always welcome!
Good luck with all your research and investing. Even the best most clean cases can get trampled on. Good DD in not always rewarded.
Best of luck
HS
I appreciate your candor and approach. It is certainly posible that NNVC has not been perfect at executing its business and developmental iniciatives. However is sincerely doubt anything they may have done was nefarious in any way. Do they want to protect their interests, I would think so. Are they a group of honest doctors trying to save lives, I also think that is true. Are they out there to steal from investors, I think not. Is it possible they may have headwinds due to possible misteps and/or mistakes...well of course.
Overall though, you simply appear to be a very cautious investor. The fact that such a cautious investor is considering the merits of NNVC, I see as a plus.
Welcome aboard. All thoughtfull comments that are made without malice or without manipulative motives are always welcome!
Good luck with all your research and investing. Even the best most clean cases can get trampled on. Good DD in not always rewarded.
Best of luck
HS
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
